Related Experiment Videos
Effect of nicomol on HDL cholesterol level
Insights
Nicomol treatment improved lipid profiles in cardiovascular and liver diseases. It increased high-density lipoprotein (HDL) cholesterol and decreased total cholesterol, beneficial for atherosclerosis patients.
Area of Science:
- Cardiology
- Biochemistry
- Pharmacology
Background:
- Cardiovascular diseases often involve atherosclerosis, characterized by altered lipid profiles, including low high-density lipoprotein (HDL) cholesterol.
- Serum lipid levels, particularly total cholesterol and HDL cholesterol, are critical indicators in managing cardiovascular and liver diseases.
- Low HDL cholesterol is a significant risk factor for atherosclerosis and related cardiovascular events.
Purpose of the Study:
- To investigate the effect of Nicomol, a nicotinic acid derivative, on serum lipid levels in patients with cardiovascular diseases and potential atherosclerosis.
- To evaluate the impact of Nicomol on total cholesterol and HDL cholesterol concentrations.
- To assess changes in the total/HDL cholesterol ratio following Nicomol treatment.
Main Methods:
- Serum HDL cholesterol was measured using a precipitation method with dextran sulfate and Mg++.
- Total cholesterol levels were also monitored.
- Patients received a daily dose of 1,200 mg of Nicomol for 1 to 3 months.
Main Results:
- Nicomol treatment led to a mean increase in HDL cholesterol of 3 to 5 mg/dl.
- Total cholesterol levels decreased by 14 to 15 mg/dl.
- The total/HDL cholesterol ratio was reduced by 0.8 (after 3 months) to 0.9 (after 1 month), with statistical significance (p < 0.05).
- Similar reductions in HDL cholesterol were observed in parenchymal and obstructive liver diseases with normal total cholesterol, excluding fulminant hepatitis and intrahepatic cholestasis.
Conclusions:
- Nicomol effectively improves lipid profiles in patients with cardiovascular diseases and potential atherosclerosis.
- The drug demonstrates a favorable impact on cholesterol levels, reducing the total/HDL cholesterol ratio.
- Nicomol may also influence HDL cholesterol levels in certain liver diseases, warranting further investigation.
Abstract:
In cardiovascular diseases with potential atherosclerosis, the serum concentration of HDL cholesterol as determined by a precipitation method with dextran sulfate and Mg++ was lower while that of total cholesterol was normal or elevated. Treatment with a daily dose of 1,200 mg of Nicomol, a derivative of nicotinic acid, for 1 to 3 months increased the mean HDL cholesterol level by 3 to 5 mg/dl and reduced the total cholesterol level by 14 to 15 mg/dl and total/HDL cholesterol ratio by 0.8 (3 months) to 0.9 (1 month, p less than 0.05). Similar decreases in HDL cholesterol concentration were also found in parenchymal and obstructive liver diseases with normal total cholesterol values except in fulminant hepatitis and intrahepatic cholestasis.